RESUMEN
The assessment of mood disorders and addiction linked to the practice of chemsex is of interest given the psychoactive substances used. The aim of this study was to assess risky sexual and addictive behavior to chemsex and related anxiety/depression symptoms in individuals receiving HIV pre-exposure prophylaxis (PrEP). In this cross-sectional study, all adults presenting for PrEP renewal at French sexual health centers were enrolled from January 2018 to March 2019. Participants completed a questionnaire on chemsex (i.e., the use of psychoactive substances before/during sex), including adapted Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) to chemsex addiction (questions of ASSIST were modified to focus on chemsex). Anxiety/depression was assessed with the Hospital Anxiety and Depression Scale. In the last 3 months before enrollment, 39.8% (94/236) of participants reported chemsex. The main psychoactive substances consumed during chemsex were cathinones (74.6%), gamma-hydroxybutyrate (66.3%), and other psychostimulants (60%). The median score of the chemsex-focused ASSIST was 8 [IQR25-75 : 3-15]; 72.2% of participants had a score justifying at least a brief intervention (>4). In multivariate analyses, anxiety and cathinones consumption were associated with an ASSIST score >4: OR 13.65 (95% CI 1.68-662.7), P = 0.0062, and OR 8.468 (95% CI 2.066-43.059), P = 0.0014, respectively. The level of addiction to the practice of chemsex can be difficult to estimate for the user, and the ASSIST makes it possible to evaluate this addiction and to direct the subjects toward specialized consultations of addictology, sexual health, or PrEP renewals. The implementation of the modified ASSIST in these consultations can allow early systematic screening and counseling.
Asunto(s)
Conducta Adictiva , Infecciones por VIH , Profilaxis Pre-Exposición , Trastornos Relacionados con Sustancias , Adulto , Masculino , Humanos , Homosexualidad Masculina/psicología , Infecciones por VIH/diagnóstico , Infecciones por VIH/prevención & control , Trastornos del Humor/prevención & control , Estudios Transversales , Trastornos Relacionados con Sustancias/prevención & controlAsunto(s)
Deformidades Adquiridas de la Mano/microbiología , Mycobacterium tuberculosis/aislamiento & purificación , Infecciones Oportunistas/microbiología , Pulgar/microbiología , Tuberculosis Cutánea/microbiología , Tuberculosis Miliar/microbiología , Anciano , Antituberculosos/uso terapéutico , Femenino , Deformidades Adquiridas de la Mano/diagnóstico , Deformidades Adquiridas de la Mano/tratamiento farmacológico , Deformidades Adquiridas de la Mano/inmunología , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/inmunología , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/inmunología , Pulgar/patología , Resultado del Tratamiento , Tuberculosis Cutánea/diagnóstico , Tuberculosis Cutánea/tratamiento farmacológico , Tuberculosis Cutánea/inmunología , Tuberculosis Miliar/diagnóstico , Tuberculosis Miliar/tratamiento farmacológico , Tuberculosis Miliar/inmunologíaRESUMEN
BACKGROUND: Ultra low dose chest computed tomography (CT) acquisitions have been used for selected emergency room patients with acute dyspnea or minor thoracic trauma. The purpose of this study was to evaluate the diagnostic performance of ultra-low-dose (ULD) chest CT for detecting viral pneumonia patterns compared to standard (STD) dose chest CT. METHODS: All consecutive adult patients with two non-enhanced chest CT acquisitions, one STD and one ULD, for suspicion of viral pneumonia between March 5th and April 2nd 2020 were included. CT results were divided into two groups: non-viral pneumonia CT or compatible with viral pneumonia CT based on viral pneumonia CT patterns: ground-glass opacity (GGO), consolidation, crazy paving, air bronchogram signs and fibrous stripes. The diagnostic performance of ULD CT for suspicion of viral pneumonia was evaluated. For CTs compatible with viral pneumonia, CT pattern detection on ULD CT was assessed and STD CT was used as a reference. RESULTS: The study included 380 patients with 97 CTs (25.5%) compatible with viral pneumonia. The mean effective doses (EDs) were 1.66 (1.29; 2.18) mSv for STD and 0.20 (0.18; 0.22) mSv for ULD CT (P<0.001). The sensitivity and specificity of ULD CT for viral pneumonia detection were 98.9% and 99.0%, respectively. GGO, consolidation and fibrous stripes were equally visible in STD and ULD in 100% (n=97), 36% (n=35) and 23% (n=22) of compatible viral pneumonia-CT patients, respectively. Air bronchogram sign detection was equivalent, concerning 23% (n=22) of patients in STD and 22% (n=21) in ULD. Crazy paving was visible in 24% (n=23) of patients in STD and only 8% (n=8) in ULD (P=0.003). CONCLUSIONS: In comparison to STD dose chest CT, ULD chest CT, with a mean reduction dose of 88.0%, has comparable diagnostic performance for detecting viral pneumonia on CT.
RESUMEN
Although cardiotoxic effects of highly active antiretroviral therapy (HAART) are a growing concern, there is a lack of prospective studies of subclinical involvement of the heart in human immunodeficiency virus (HIV)-infected patients. This study evaluated noninvasively cardiac morphologic characteristics and function in HIV-positive (HIV(+)) men receiving HAART for > or =2 years with no clinical evidence of cardiovascular disease. Echocardiography at rest, including tissue Doppler imaging and exercise testing, were performed in 30 HIV(+) men (age 42.1 +/- 4.7 years, duration of HIV infection 10.4 +/- 4.7 years, duration of HAART 5.3 +/- 2.1 years) and 26 age-matched healthy controls. At rest, HIV(+) patients had similar left ventricular (LV) mass indexed to height(2.7) (40.6 +/- 9.5 vs 37.5 +/- 9.3 g/m; p >0.05), but a higher prevalence of LV diastolic dysfunction (abnormal relaxation or pseudonormal filling pattern in 64% of patients vs 12% of controls; p <0.001). LV systolic function indexes were significantly lower (ejection fraction 60.4 +/- 8.7% vs 66.9 +/- 6.9%; p <0.01, and tissue Doppler imaging peak systolic velocity 11.4 +/- 1.6 vs 13.5 +/- 2.2 cm/s; p <0.001). Pulmonary artery pressure was higher in patients compared with controls (32.1 +/- 5.4 vs 26.1 +/- 6.5 mm Hg; p <0.001). Exercise testing showed decreased exercise tolerance in HIV(+) patients, with no case of myocardial ischemia. In conclusion, subclinical cardiac abnormalities are frequently observed in HIV(+) patients on HAART. The usefulness of systematic noninvasive screening in this population should be considered. GECEM study no. 30: National Agency for AIDS Research (ANRS).
Asunto(s)
Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/fisiopatología , Disfunción Ventricular Izquierda/fisiopatología , Adulto , Velocidad del Flujo Sanguíneo/fisiología , Presión Sanguínea/fisiología , Estudios de Casos y Controles , Diástole/fisiología , Ecocardiografía , Prueba de Esfuerzo , Tolerancia al Ejercicio/fisiología , Frecuencia Cardíaca/fisiología , Ventrículos Cardíacos/diagnóstico por imagen , Humanos , Masculino , Estudios Prospectivos , Descanso/fisiología , Volumen Sistólico/fisiología , Sístole/fisiología , Disfunción Ventricular Izquierda/diagnóstico por imagenRESUMEN
OBJECTIVE: To explore whether airway obstruction is associated with HIV in a cohort of HIV-infected and uninfected smokers. METHODS: People living with HIV (PLWHIV) participated in the ANRS EP48 HIV CHEST study, an early lung cancer diagnosis study with low-dose chest tomography. HIV-uninfected study participants were from the CONSTANCES cohort. Inclusion criteria were an age greater than 40 years, a smoking history of at least 20 pack-years, and for PLWHIV, a CD4 T-lymphocyte nadir less than 350/µl and last CD4 cell count more than 100 cells/µl. Two randomly selected HIV-uninfected study participants were matched by age and sex with one PLWHIV. Prebronchodilatator forced expiratory volume in 1âs (FEV1) to forced vital capacity (FVC) ratio was the primary outcome, and association of FEV1/FVC ratio less than 0.70 and FEV1 less than 80% of the theoretical value, as a proxy of chronic obstructive pulmonary disease, the secondary outcome. RESULTS: In total, 351 PLWHIV and 702 HIV-uninfected study participants were included. Median age was 50 years, and 17% of study participants were women. Plasma HIV RNA was less than 50 copies/ml in 89% of PLWHIV, with a median CD4 cell count of 573 cells/µl. HIV (ß -2.19), age (per 10 years increase; ß -2.81), tobacco use (per 5 pack-years increase; ß -0.34), and hepatitis C virus serology (ß-2.50) were negatively associated with FEV1/FVC. HIV [odds ratio (OR: 1.72)], age (per 10 years increase; OR 1.77), and tobacco use (per 5 pack-years increase; OR 1.11) were significantly associated with the secondary outcome. CONCLUSION: Our study found a significant association of airway obstruction with HIV status in smokers aged more than 40 years with previous immunodeficiency.
Asunto(s)
Infecciones por VIH/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Fumar/efectos adversos , Adolescente , Adulto , Factores de Edad , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Adulto JovenRESUMEN
OBJECTIVE: Lung cancer screening with chest computed tomography (CT) is beneficial in smokers aged 55 to 74 years. We studied the risks, benefits and feasibility of early lung cancer diagnosis with CT in HIV-infected smokers. DESIGN AND SETTING: French, multicentre, single round chest CT study in France, realized between February 2011 and June 2012. PARTICIPANTS: Patients were HIV-infected smokers at least 40 years, at least 20 pack-years, with a CD4 T-lymphocyte nadir count below 350 cells/µl. INTERVENTION: Single chest CT with a proposed standardized workup algorithm of positive images. MAIN OUTCOME MEASURE: The outcome was the number of histologically proven lung cancers diagnosed by CT with a 2-year follow-up. RESULTS: Median age of the 442 included patients was 49.8 years, 81.6% were under 55 years, 84% were men, median smoking was 30 pack-years, median nadir and last CD4 cell counts were 168 and 574 cells/µl, respectively, and 90% of patients had a plasma HIV RNA below 50âcopies/ml. A positive image at baseline was reported in 94 (21%) patients, and 15 (3.4%) patients had 18 invasive procedures with no serious adverse events. Lung cancer was diagnosed in 10 patients (six at early stages), of which nine (2.0%, 95% confidence interval: 0.9-3.8) were CT detected, and eight in patients below 55 years. CONCLUSION: Early lung cancer diagnosis with CT in HIV-infected smokers was feasible, safe, and yielded a significant number of cancers. Lung cancer screening of HIV-infected smokers with an important history of immunodeficiency revealed a substantial number of cancers at younger ages than the targeted range in the general population.
Asunto(s)
Infecciones por VIH/complicaciones , Neoplasias Pulmonares/diagnóstico , Pulmón/diagnóstico por imagen , Tamizaje Masivo/métodos , Fumar/efectos adversos , Tomografía Computarizada por Rayos X/métodos , Adulto , Anciano , Diagnóstico Precoz , Femenino , Francia , Humanos , Masculino , Tamizaje Masivo/efectos adversos , Persona de Mediana Edad , Estudios Prospectivos , Tomografía Computarizada por Rayos X/efectos adversosRESUMEN
We describe four cases of hand osteoarthritis in patients with HIV infection under antiretroviral treatment. A 36-year-old HIV-infected man came for consultation in 2007 with hand osteoarthritis. He was diagnosed HIV positive by sexual transmission in 1997. A 52-year-old HIV-infected woman came for consultation with hand osteoarthritis started in 2006. She was diagnosed HIV positive in 1986 by sexual transmission. A 57-year-old man presented hand osteoarthritis. This former IV drug user was diagnosed HIV positive in 1989. A 61-year-old HIV-infected man presented with hand osteoarthritis started in 2010. He had been contaminated with HIV in 1990 by sexual transmission. For all patients, there were neither clinical nor biological manifestations suggesting inflammatory arthritis. X-rays showed signs of hand osteoarthritis. CD4 cell count was over 500/mm(3) and the viral load was below 20 copies/mL under treatments. These four cases show osteoarthritis in HIV-infected patients. Hand osteoarthritis did not seem to be linked to aging or to an antiretroviral treatment's side effect, but rather to the HIV infection itself, and it may pass through a metabolic syndrome. We described a possible association between early-developed hand osteoarthritis and HIV-infected patients. Clinicians should consider osteoarthritis when they are confronted with HIV-infected patients with chronic hand pain.
Asunto(s)
Antirretrovirales/uso terapéutico , Anticuerpos Anti-VIH/inmunología , Seropositividad para VIH/tratamiento farmacológico , VIH/inmunología , Osteoartritis/etiología , Adulto , Femenino , Seropositividad para VIH/complicaciones , Mano , Humanos , Masculino , Persona de Mediana Edad , Osteoartritis/diagnóstico , Factores de TiempoRESUMEN
We describe a human immunodeficiency virus (HIV)-infected patient with chronic active hepatitis B. The patient presented with acute clinical hepatitis during highly active antiretroviral therapy concomitant with immunovirological improvement of HIV infection. The hepatitis resolved within a few weeks despite the pursuit of antiretroviral drugs. Hepatitis B tests, which remained unchanged after two cycles of interferon alfa therapy and continuous administration of lamivudine, were improved with the clearance of hepatitis B virus (HBV) early antigen (HBeAg), the detection of antibody to HBV early antigen (HBeAb) and the undetectability of serum HBV DNA. Several months after this episode, HBV and HIV tests are still controlled.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Terapia Antirretroviral Altamente Activa/efectos adversos , Hepatitis B/complicaciones , Enfermedad Aguda , Estudios de Seguimiento , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Hepatitis B Crónica/complicaciones , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Antiinflamatorios no Esteroideos/envenenamiento , Infecciones por VIH/complicaciones , Psoriasis/tratamiento farmacológico , Salicilatos/envenenamiento , Absorción Cutánea , Administración Cutánea , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Humanos , Masculino , Salicilatos/uso terapéuticoAsunto(s)
Antituberculosos/uso terapéutico , Infecciones por VIH/complicaciones , Síndrome Inflamatorio de Reconstitución Inmune/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Enfermedades del Sistema Nervioso/etiología , Talidomida/uso terapéutico , Tuberculosis/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/inmunología , Antirretrovirales/uso terapéutico , Terapia Antirretroviral Altamente Activa , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/psicología , Humanos , Síndrome Inflamatorio de Reconstitución Inmune/complicaciones , Síndrome Inflamatorio de Reconstitución Inmune/psicología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Mycobacterium tuberculosis/inmunología , Mycobacterium tuberculosis/aislamiento & purificación , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades del Sistema Nervioso/psicología , Examen Neurológico , Paresia/etiología , Resultado del Tratamiento , Tuberculosis/tratamiento farmacológicoAsunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Interferones/uso terapéutico , Sarcoma de Kaposi/tratamiento farmacológico , Neoplasias Cutáneas/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Fármacos Anti-VIH/uso terapéutico , Recuento de Linfocito CD4 , Terapia Combinada , Femenino , Infecciones por VIH/tratamiento farmacológico , VIH-1 , Humanos , Sarcoma de Kaposi/complicaciones , Neoplasias Cutáneas/tratamiento farmacológico , Resultado del Tratamiento , Carga Viral , Adulto JovenRESUMEN
Resting and exercise cardiac function, skeletal muscle oxygenation and whole-body aerobic exercise capacities were evaluated prospectively in cardiac symptom-free HIV men receiving antiretroviral therapies and in healthy controls matched for age, physical activity, smoking and body surface area. HIV patients showed resting cardiac dysfunction, altered cardiac responses to exercise and depressed exercise tolerance. Exercise stroke volume kinetics and muscle oxygenation were impaired in HIV patients, especially in those with resting diastolic dysfunction.
Asunto(s)
Ejercicio Físico/fisiología , Infecciones por VIH/fisiopatología , Disfunción Ventricular Izquierda/virología , Adulto , Umbral Anaerobio/fisiología , Terapia Antirretroviral Altamente Activa , Electrocardiografía , Prueba de Esfuerzo , Tolerancia al Ejercicio/fisiología , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Músculo Esquelético/metabolismo , Estudios Prospectivos , Volumen Sistólico/fisiología , Disfunción Ventricular Izquierda/fisiopatologíaRESUMEN
We describe 7 cases of renal tubular injury in HIV-infected patients receiving an antiretroviral regimen containing tenofovir. Our patients (5 women and 2 men) developed renal tubular dysfunction, with hypophosphatemia, normoglycemic glycosuria, proteinuria, and decrease of creatinine clearance. The first biologic signs of renal toxicity were observed after duration of tenofovir treatment from 5 weeks to 16 months, and they resolved less than 4 months after discontinuation of tenofovir. Six patients had a low body weight (<60 kg). Five patients received low doses of ritonavir, and 1 received didanosine. In 5 patients, the signs resolved with the discontinuation of only the tenofovir. A renal biopsy performed in 1 patient was consistent with tubulointerstitial injury. Proximal tubulopathy appears to be a rare adverse effect of long-term tenofovir therapy. In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction.